These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30924452)

  • 21. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.
    Hansel DE; Nakayama M; Luo J; Abukhdeir AM; Park BH; Bieberich CJ; Hicks JL; Eisenberger M; Nelson WG; Mostwin JL; De Marzo AM
    Prostate; 2009 May; 69(6):603-9. PubMed ID: 19125417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroendocrine differentiation of prostate cancer.
    Li Z; Chen CJ; Wang JK; Hsia E; Li W; Squires J; Sun Y; Huang J
    Asian J Androl; 2013 May; 15(3):328-32. PubMed ID: 23503426
    [No Abstract]   [Full Text] [Related]  

  • 23. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
    Yuan TC; Veeramani S; Lin MF
    Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroendocrine tumors of the prostate.
    Fine SW
    Mod Pathol; 2018 Jan; 31(S1):S122-132. PubMed ID: 29297494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells.
    Jain P; Clermont PL; Desmeules F; Zoubeidi A; Neveu B; Pouliot F
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30626088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer.
    Ku SY; Wang Y; Garcia MM; Yamada Y; Mizuno K; Long MD; Rosario S; Chinnam M; Al Assaad M; Puca L; Kim MJ; Bakht MK; Venkadakrishnan VB; Robinson BD; Acosta AM; Wadosky KM; Mosquera JM; Goodrich DW; Beltran H
    J Clin Invest; 2024 Jul; 134(17):. PubMed ID: 39024561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features.
    Liu Q; Russell MR; Shahriari K; Jernigan DL; Lioni MI; Garcia FU; Fatatis A
    Cancer Res; 2013 Jun; 73(11):3297-305. PubMed ID: 23536554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.
    Aggarwal RR; Quigley DA; Huang J; Zhang L; Beer TM; Rettig MB; Reiter RE; Gleave ME; Thomas GV; Foye A; Playdle D; Lloyd P; Chi KN; Evans CP; Lara PN; Feng FY; Alumkal JJ; Small EJ
    Mol Cancer Res; 2019 Jun; 17(6):1235-1240. PubMed ID: 30918106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells.
    Tawadros T; Alonso F; Jichlinski P; Clarke N; Calandra T; Haefliger JA; Roger T
    Endocr Relat Cancer; 2013 Feb; 20(1):137-49. PubMed ID: 23207293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
    Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
    Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome.
    Abdulfatah E; Reichert ZR; Davenport MS; Chinnaiyan AM; Dadhania V; Wang X; Mannan R; Kunju LP; Hollenbeck BK; Montgomery JS; Kaffenberger SD; Morgan TM; Alva AS; Palapattu GS; Vaishampayan UN; Alumkal JJ; Spratt DE; Udager AM; Mehra R
    Med Oncol; 2021 Feb; 38(3):26. PubMed ID: 33586037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.
    Alshalalfa M; Liu Y; Wyatt AW; Gibb EA; Tsai HK; Erho N; Lehrer J; Takhar M; Ramnarine VR; Collins CC; Den RB; Schaeffer EM; Davicioni E; Lotan TL; Bismar TA
    Int J Cancer; 2019 Dec; 145(12):3453-3461. PubMed ID: 31125117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The histogenesis of small cell carcinoma of the prostate. An immunohistochemical study.
    Schron DS; Gipson T; Mendelsohn G
    Cancer; 1984 Jun; 53(11):2478-80. PubMed ID: 6324985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroendocrine differentiation in the progression of prostate cancer.
    Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
    Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells.
    Ding M; Lin B; Li T; Liu Y; Li Y; Zhou X; Miao M; Gu J; Pan H; Yang F; Li T; Liu XY; Li R
    Oncotarget; 2015 Apr; 6(10):7686-700. PubMed ID: 25797256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
    Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
    Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delineating the Molecular Events Underlying Development of Prostate Cancer Variants with Neuroendocrine/Small Cell Carcinoma Characteristics.
    Kanayama M; Luo J
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of neuroendocrine cells in prostate cancer: a comprehensive review of current literature and subsequent rationale to broaden and integrate current treatment modalities.
    Lugnani F; Simone G; Biava PM; Ablin RJ
    Curr Med Chem; 2014; 21(9):1082-92. PubMed ID: 24304274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells.
    Labrecque MP; Takhar MK; Nason R; Santacruz S; Tam KJ; Massah S; Haegert A; Bell RH; Altamirano-Dimas M; Collins CC; Lee FJ; Prefontaine GG; Cox ME; Beischlag TV
    Oncotarget; 2016 Apr; 7(17):24284-302. PubMed ID: 27015368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.
    Akamatsu S; Wyatt AW; Lin D; Lysakowski S; Zhang F; Kim S; Tse C; Wang K; Mo F; Haegert A; Brahmbhatt S; Bell R; Adomat H; Kawai Y; Xue H; Dong X; Fazli L; Tsai H; Lotan TL; Kossai M; Mosquera JM; Rubin MA; Beltran H; Zoubeidi A; Wang Y; Gleave ME; Collins CC
    Cell Rep; 2015 Aug; 12(6):922-36. PubMed ID: 26235627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.